Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT03616886 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT03616886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03616886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Lead sponsor
Jules Bordet Institute
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 28, 2018
Completion date
December 31, 2028
Enrollment
129 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer